Leading Product Revenue

August 07, 2025

(¥ million)

Brand name	Active Ingredients	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredients	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr-Jun	Apr-Sep (estimated)	Annual (estimated)
Viltepso				17,530	21,782	5,194	10,800	21,500
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(1,198)	(2,400)	(4,800)
(U.S.)				(13,123)	(17,117)	(3,995)	(8,400)	(16,700)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	4,375	8,300	16,800
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	1,447	3,500	7,300
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	1,180	2,600	5,200
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,022	1,700	3,100
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Apr-2014	377	2,067	887	1,700	4,000
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	650	1,200	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	571	1,000	2,000
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	557	1,250	2,500
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-	-
Profit in co-promotion				8,658	9,170	2,517	4,700	9,600
Revenues from the licensing of industrial property rights				40,304	45,585	11,511	22,800	47,500
Pharmaceuticals				125,105	138,654	34,163	71,000	143,000
Functional Food				23,150	21,577	5,382	10,500	23,000
Revenue				148,255	160,232	39,546	81,500	166,000

Brand name	Active Ingredients	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Sales FY2025 (IFRS)
Brand name	Active Ingredients	Indications	Launch Date	Sales FY2023 (IFRS)	Sales FY2024 (IFRS)	Apr-Jun	Apr-Sep (estimated)	Annual (estimated)
Viltepso				17,530	21,782	5,194	10,800	21,500
(Japan)	viltolarsen	Duchenne muscular dystrophy	Japan May-2020 U.S. Aug-2020	(4,407)	(4,664)	(1,198)	(2,400)	(4,800)
(U.S.)				(13,123)	(17,117)	(3,995)	(8,400)	(16,700)
Uptravi	selexipag	pulmonary arterial hypertension/ chronic thromboembolic pulmonary hypertension	Nov-2016/ Aug-2021	12,918	14,971	4,375	8,300	16,800
Vyxeos	daunorubicin / cytarabine	high-risk acute myeloid leukemia	May-2024	-	5,139	1,447	3,500	7,300
Gazyva	obinutuzumab	CD20-positive follicular lymphoma/ CD20-positive chronic lymphocytic leukemia	Aug-2018/ Dec-2022	4,695	4,821	1,180	2,600	5,200
Vidaza	azacitidine	myelodysplastic syndrome/ acute myeloid leukemia	Mar-2011/ Mar-2021	10,383	5,109	1,022	1,700	3,100
Fintepla	fenfluramine hydrochloride	seizures associated with Dravet syndrome/ seizures associated with Lennox-Gastaut syndrome	Apr-2014	377	2,067	887	1,700	4,000
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	2,221	2,364	650	1,200	2,500
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	3,927	2,728	571	1,000	2,000
Cialis	tadalafil	erectile dysfunction	Jul-2009	2,499	2,425	557	1,250	2,500
CAP-1002 (U.S.)	deramiocel	Duchenne muscular dystrophy cardiomyopathy	Filed	-	-	-	-	-
Profit in co-promotion				8,658	9,170	2,517	4,700	9,600
Revenues from the licensing of industrial property rights				40,304	45,585	11,511	22,800	47,500
Pharmaceuticals				125,105	138,654	34,163	71,000	143,000
Functional Food				23,150	21,577	5,382	10,500	23,000
Revenue				148,255	160,232	39,546	81,500	166,000

Back Number

Related Link

Nippon Shinyaku’s DNA

Research & Development

Business/Financial Information